Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x.

PMID:
29473097
2.

A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups.

Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Erratum in: Ann Hematol. 2018 Feb 23;:.

PMID:
29392425
3.

Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.

Lhermitte L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, Sedek L, Bras AE, Gaipa G, Sobral da Costa E, Novakova M, Sonneveld E, Buracchi C, de Sá Bacelar T, Te Marvelde JG, Trinquand A, Asnafi V, Szczepanski T, Matarraz S, Lopez A, Vidriales B, Bulsa J, Hrusak O, Kalina T, Lecrevisse Q, Martin Ayuso M, Brüggemann M, Verde J, Fernandez P, Burgos L, Paiva B, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ.

Leukemia. 2018 Apr;32(4):874-881. doi: 10.1038/leu.2017.313. Epub 2017 Nov 1.

4.

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile.

Martín-Martín L, López A, Vidriales B, Caballero MD, Rodrigues AS, Ferreira SI, Lima M, Almeida S, Valverde B, Martínez P, Ferrer A, Candeias J, Ruíz-Cabello F, Buadesa JM, Sempere A, Villamor N, Orfao A, Almeida J.

Oncotarget. 2015 Aug 7;6(22):19204-16.

5.

Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C.

Leuk Res. 2014 May;38(5):551-6. doi: 10.1016/j.leukres.2014.02.001. Epub 2014 Feb 10.

PMID:
24655806
6.

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine.

Bennett TA, Montesinos P, Moscardo F, Martinez-Cuadron D, Martinez J, Sierra J, García R, de Oteyza JP, Fernandez P, Serrano J, Fernandez A, Herrera P, Gonzalez A, Bethancourt C, Rodriguez-Macias G, Alonso A, Vera JA, Navas B, Lavilla E, Lopez JA, Jimenez S, Simiele A, Vidriales B, Gonzalez BJ, Burgaleta C, Hernandez Rivas JA, Mascuñano RC, Bautista G, Perez Simon JA, Fuente Ade L, Rayón C, Troconiz IF, Janda A, Bosanquet AG, Hernandez-Campo P, Primo D, Lopez R, Liebana B, Rojas JL, Gorrochategui J, Sanz MA, Ballesteros J.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):305-18. doi: 10.1016/j.clml.2013.11.006. Epub 2013 Nov 15.

7.

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

Martínez-Cuadrón D, Montesinos P, Oriol A, Salamero O, Vidriales B, Bergua J, Herrera P, Vives S, Sanz J, Carpio C, Rodríguez-Veiga R, Moscardó F, Sanz MA.

Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.

PMID:
24081577
8.

Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.

García-Sanz R, Ocio E, Caballero A, Magalhães RJ, Alonso J, López-Anglada L, Villaescusa T, Puig N, Hernández JM, Fernández-Calvo J, Aguilar A, Martín A, López R, Paiva B, Orfao A, Vidriales B, San-Miguel JF, Del Carpio D.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):168-71. doi: 10.3816/CLML.2011.n.040.

PMID:
21856552
9.

Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry.

Ocio EM, del Carpio D, Caballero Á, Alonso J, Paiva B, Pesoa R, Villaescusa T, López-Anglada L, Vidriales B, García-Sanz R.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):93-5. doi: 10.3816/CLML.2011.n.017.

PMID:
21454201
10.

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.

Ribera JM, Oriol A, González M, Vidriales B, Brunet S, Esteve J, Del Potro E, Rivas C, Moreno MJ, Tormo M, Martín-Reina V, Sarrá J, Parody R, de Oteyza JP, Bureo E, Bernal MT; Programa Español de Tratamiento en Hematología; Grupo Español de Trasplante Hemopoyético Groups.

Haematologica. 2010 Jan;95(1):87-95. doi: 10.3324/haematol.2009.011221. Epub 2009 Oct 1.

11.

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.

Díez-Campelo M, Pérez-Simón JA, Pérez J, Alcoceba M, Richtmon J, Vidriales B, San Miguel J.

Am J Hematol. 2009 Mar;84(3):149-52. doi: 10.1002/ajh.21340.

12.

Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria.

Hernández-Campo PM, Almeida J, Acevedo MJ, Sánchez ML, Alberca I, Vidriales B, Martínez E, Romero JR, Orfao A.

Transfusion. 2008 Jul;48(7):1403-14. doi: 10.1111/j.1537-2995.2008.01686.x. Epub 2008 Apr 16.

PMID:
18422849
13.

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines.

Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, López-Holgado N, Maiso P, Alberca M, Villarón E, Schenkein D, Pandiella A, San Miguel J.

Blood. 2006 May 1;107(9):3575-83. Epub 2005 Nov 10.

14.

Cell cycle analysis of Waldenstrom's macroglobulinemia.

Ocio EM, Mateo G, Vidriales B, Lopez-Berges MC, Garcia-Sanz R, Hernandez JM, Orfao A, San Miguel JF.

Clin Lymphoma. 2005 Mar;5(4):250-2.

PMID:
15794858
15.

Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma.

Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, Gutierrez NC, Orfao A, San Miguel JF.

Clin Lymphoma. 2005 Mar;5(4):241-5.

PMID:
15794856
16.

Immunophenotypic analysis of myelodysplastic syndromes.

Del Cañizo MC, Fernández ME, López A, Vidriales B, Villarón E, Arroyo JL, Ortuño F, Orfao A, San Miguel JF.

Haematologica. 2003 Apr;88(4):402-7.

17.

Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.

Sánchez ML, Almeida J, Vidriales B, López-Berges MC, García-Marcos MA, Moro MJ, Corrales A, Calmuntia MJ, San Miguel JF, Orfao A.

Leukemia. 2002 Aug;16(8):1460-9.

18.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.

Leukemia. 2002 Aug;16(8):1423-31. Review.

19.

Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.

Suárez L, Vidriales B, García-Laraña J, López A, Martínez R, Martín-Reina V, Tormo M, González-San Miguel JD, Lavilla E, García-Boyero R, Orfao A, San Miguel JF; PETHEMA Cooperative Group.

Haematologica. 2001 Dec;86(12):1287-95.

20.

BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation.

Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T, Bjorklund E, Biondi A, van den Beemd MW, Baars E, Vidriales B, Parreira A, van Dongen JJ, San Miguel JF, Orfao A; BIOMED-I.

Leukemia. 2001 Aug;15(8):1185-92.

PMID:
11480560
21.

Factors that influence long-term hematopoietic function following autologous stem cell transplantation.

Amigo ML, del Cañizo MC, Caballero MD, Vazquez L, Corral M, Vidriales B, Brufau A, San Miguel JF.

Bone Marrow Transplant. 1999 Aug;24(3):289-93.

22.

Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.

Ciudad J, Orfao A, Vidriales B, Macedo A, Martínez A, González M, López-Berges MC, Valverde B, San Miguel JF.

Haematologica. 1998 Dec;83(12):1069-75.

23.

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia.

Ciudad J, San Miguel JF, López-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernández J, Moro MJ, Mateos MV, Orfao A.

J Clin Oncol. 1998 Dec;16(12):3774-81.

PMID:
9850021
24.

[Fulminant angiopathy caused by allogenic transplantation of bone marrow with cerebral involvement: clinico-pathologic correlation].

Guerrero AL, Pérez-Simón JA, Cuñado A, Cacho J, Vidriales B.

An Med Interna. 1998 Oct;15(10):545-7. Review. Spanish.

PMID:
9844232
25.

Functional expression of MDR-1 in acute myeloid leukemia: correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics.

Martínez A, San Miguel JF, Valverde B, Bárez A, Moro MJ, García-Marcos MA, Pérez-Simón JA, Vidriales B, Orfao A.

Ann Hematol. 1997 Sep;75(3):81-6.

PMID:
9368475
26.

BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.

Caballero MD, Rubio V, Rifon J, Heras I, García-Sanz R, Vázquez L, Vidriales B, del Cañizo MC, Corral M, Gonzalez M, León A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF.

Bone Marrow Transplant. 1997 Sep;20(6):451-8.

27.

[Controversies in the determination of CD34].

Orfao A, López-Berges MC, Vidriales B, Ercilla G, Nieto MJ, Caballero MD, San Miguel J.

Sangre (Barc). 1997 Apr;42 Suppl 1:7-9. Spanish. No abstract available.

PMID:
9381309
28.

[Autologous transplant with BEAM protocol in lymphoma].

Caballero D, Rubio V, Rifon J, Heras I, García-Sanz R, Vidriales B, Pérez-Simón JA, del Cañizo C, González M, León A, Jean-Paul E, Rocha E, Vicente V, San Miguel JF.

Sangre (Barc). 1997 Apr;42 Suppl 1:46-9. Spanish. No abstract available.

PMID:
9381303
29.

[The immunology laboratory in malignant blood diseases].

López Berges MC, Vidriales B, Ocqueteau M, Orfao A.

Sangre (Barc). 1996 Aug;41(4):281-8. Review. Spanish. No abstract available.

PMID:
8984669
30.

Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation.

Sanfructuoso C, Caballero MD, Garcia-Sanz R, Vidriales B, Vazquez L, San Miguel JF.

Eur J Haematol. 1996 Mar;56(3):181-3. No abstract available.

PMID:
8598240
31.

[Activity of various hematopoietic growth factors on acute myeloblastic leukemia blasts].

Almeida J, del Cañizo MC, Vidriales B, Hernández MD, Galende J, San Miguel J.

Sangre (Barc). 1996 Feb;41(1):3-8. Spanish.

PMID:
8779032
32.

Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.

Macedo A, Orfao A, Ciudad J, Gonzalez M, Vidriales B, Lopez-Berges MC, Martínez A, Landolfi C, Cañizo C, San Miguel JF.

Leukemia. 1995 Nov;9(11):1896-901.

PMID:
7475281
33.

[Clonogenic cells of acute leukemia secondary to myeloproliferative and myelodysplastic syndromes].

Almeida J, del Cañizo MC, Galende J, Vidriales B, Nieto MJ, Hernández MD, Rodríguez MJ, San Miguel JF.

Sangre (Barc). 1994 Oct;39(5):331-5. Spanish.

PMID:
7754436
34.

Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry.

Orfao A, Ciudad J, Lopez-Berges MC, Lopez A, Vidriales B, Caballero MD, Valverde B, Gonzalez M, San Miguel JF.

Leuk Lymphoma. 1994;13 Suppl 1:87-90.

PMID:
8075587
35.

Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia.

Orfao A, Vidriales B, Gonzalez M, Lopez-Berges MC, del Cañizo MC, San Miguel JF.

Recent Results Cancer Res. 1993;131:369-79. No abstract available.

PMID:
8210655
36.

Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study.

Ruiz-Argüelles GJ, Lobato-Mendizábal E, San-Miguel JF, González M, Caballero MD, Ruiz-Argüelles A, Orfao A, Gómez-Almaguer D, Vidriales B, Ruiz-Reyes G, et al.

Br J Haematol. 1992 Dec;82(4):671-5.

PMID:
1482653

Supplemental Content

Loading ...
Support Center